63874-38-4

Usage

Uses

Used in Food and Beverage Industry:
Benzoic acid, 3-(aminocarbonyl)-4-hydroxy-, methyl ester is used as a flavoring agent and preservative for its ability to enhance taste and extend the shelf life of various food and beverage products. Its antimicrobial properties help prevent the growth of bacteria and fungi, ensuring product safety and quality.
Used in Cosmetic Industry:
In the cosmetic industry, Benzoic acid, 3-(aminocarbonyl)-4-hydroxy-, methyl ester is used as a fragrance ingredient to provide a pleasant scent to various cosmetic products. Its antimicrobial properties also contribute to the preservation of these products, preventing microbial contamination and ensuring product safety.
Used in Pharmaceutical Industry:
Benzoic acid, 3-(aminocarbonyl)-4-hydroxy-, methyl ester is utilized in the pharmaceutical industry as a fragrance ingredient in various medicinal products. Its antimicrobial properties can also be beneficial in preserving the quality and safety of these products.
It is important to use Benzoic acid, 3-(aminocarbonyl)-4-hydroxy-, methyl ester in accordance with safety guidelines to avoid any potential health risks.

Upstream product

• 5985-24-0 dimethyl 4-hydroxyisophthalate 
• 94633-02-0 methyl 4-benzyloxy-3-carbamoylbenzoate 
• 636-46-4 4-hydroxyisophthalic acid 
• 79128-78-2 2-hydroxy-5-(methoxycarbonyl)benzoic acid 
• 67-56-1 methanol 
• 76142-87-5 5-carboxysalicylamide 

Downstream Products

• 76142-87-5 5-carboxysalicylamide 
• 24798-47-8 2-(2-hydroxy-5-methoxycarbonylphenyl)-4H-1,3-benzoxazin-4-one 
• 1431546-52-9 C₂₅H₃₁N₃O₅ 

Relevant academic research and scientific papers

MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME

Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

Synthesis and characterization of related substances of deferasirox, an iron (Fe3+) chelating agent

Deferasirox is an orally active iron chelating agent, and during process development for deferasirox, we observed six related substances (impurities), namely deferasirox methyl ester, deferasirox salicylyl derivative, deferasirox ethyl ester, deferasirox methoxy carbonyl derivative, bis(salicyl)imide, and deferasirox-2-isomer. The present work describes the detection, origin, synthesis, and characterization of these related substances.

Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof

The present invention provides compounds of formula I: along with methods of use of these compounds as pharmaceuticals, particularly in the treatment of obesity, metabolic syndrome, atherosclerosis, cardiovascular disease, insulin resistance, diseases ass

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).